Cargando…
Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis
The use of immunotherapy has achieved great advances in the treatment of cancer. Macrophages play a pivotal role in the immune defense system, serving both as phagocytes (removal of pathogens and cancer cells) and as antigen‐presenting cells (activation of T cells). However, research regarding tumor...
Autores principales: | Yang, Hongcheng, Shao, Ruoyang, Huang, Hongxin, Wang, Xinlong, Rong, Zhili, Lin, Ying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675709/ https://www.ncbi.nlm.nih.gov/pubmed/31183992 http://dx.doi.org/10.1002/cam4.2332 |
Ejemplares similares
-
Replication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
por: Horrigan, Stephen K
Publicado: (2017) -
Expression and Prognostic Significance of CD47–SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer
por: Sugimura-Nagata, Akane, et al.
Publicado: (2021) -
Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition
por: Al-Sudani, Hussein, et al.
Publicado: (2023) -
Registered report: The CD47-signal regulated protein alpha (SIRPa)
interaction is a therapeutic target for human solid tumors
por: Chroscinski, Denise, et al.
Publicado: (2015) -
“Marker of Self” CD47 on lentiviral vectors decreases macrophage-mediated clearance and increases delivery to SIRPA-expressing lung carcinoma tumors
por: Sosale, Nisha G, et al.
Publicado: (2016)